Estimating LGBTQ+ attitudes in the US and the UK

Last registered on October 13, 2025

Pre-Trial

Trial Information

General Information

Title
Estimating LGBTQ+ attitudes in the US and the UK
RCT ID
AEARCTR-0016666
Initial registration date
September 12, 2025

Initial registration date is when the trial was registered.

It corresponds to when the registration was submitted to the Registry to be reviewed for publication.

First published
September 12, 2025, 10:49 AM EDT

First published corresponds to when the trial was first made public on the Registry after being reviewed.

Last updated
October 13, 2025, 11:29 AM EDT

Last updated is the most recent time when changes to the trial's registration were published.

Locations

There is information in this trial unavailable to the public. Use the button below to request access.

Request Information

Primary Investigator

Affiliation
Rensselaer Polytechnic Institute

Other Primary Investigator(s)

PI Affiliation
Vanderbilt University
PI Affiliation
UC Berkeley
PI Affiliation
University of Exeter

Additional Trial Information

Status
In development
Start date
2025-09-15
End date
2026-12-31
Secondary IDs
Prior work
This trial is based on or builds upon one or more prior RCTs.
Abstract
Puberty blockers are a reversible pharmaceutical intervention used to support the mental health and well-being of young people experiencing two distinct medical conditions: precocious puberty and gender dysphoria. This study employs a series of list experiments to measure public support for prescribing puberty blockers to transgender and cisgender youth in the United States and the United Kingdom and compare these attitudes. Additionally, we examine public opinion on transgender managers as well as employment anti-discrimination protections for transgender workers. By comparing list experiment estimates with direct questioning, we also assess the extent of social desirability bias in these contexts. We will also study population beliefs and other attitudes and perceptions on LGBTQ+ topics and demographics.
External Link(s)

Registration Citation

Citation
Aksoy, Billur et al. 2025. "Estimating LGBTQ+ attitudes in the US and the UK." AEA RCT Registry. October 13. https://doi.org/10.1257/rct.16666-2.0
Sponsors & Partners

There is information in this trial unavailable to the public. Use the button below to request access.

Request Information
Experimental Details

Interventions

Intervention(s)
Intervention Start Date
2025-09-15
Intervention End Date
2026-12-31

Primary Outcomes

Primary Outcomes (end points)
i) The average differences-in-means between control and treatment groups from all lists for all key sensitive statements (using the list experiment data).

ii) The answers to the direct sensitive questions (using the survey data).

iii) The differences between i) and ii).

iv) The differences in i), ii), and iii) across all key statements.

v) The differences in i), ii), and iii) over time, when possible.
Primary Outcomes (explanation)
i) The average differences-in-means between control and treatment groups from all lists for all key sensitive statements (using the list experiment data): this is the outcome variable that comes from our double list experiment technique. As explained in more detailed in the experimental design section of our pre-analysis plan registration, for a given sensitive statement, half of the subjects will see “List A” and “List B + Key Sensitive Item” and the remaining half will see “List A + Key Sensitive Item” and “List B”. We will take the difference in means based on the answers provided to “List A” and “List A + Key Sensitive Item”, next take the difference in means based on the answers provided to “List B” and “List B + Key Sensitive Item”, and then we will calculate the average of these two differences in means. This gives us the estimated share of the population with the key sensitive attribute.

ii) The answers to the direct sensitive questions (using the survey data): these are baseline estimates of the share of the population with the key sensitive attributes (without accounting for social desirability bias).

iii) The differences between i) and ii): this is the estimated size of the social desirability bias.

iv) The differences in i), ii), and iii) across all key statements: these are the differences in in attitudes using list experiment, direct survey, the size of the social desirability bias across all key statements. Key statements are indicated below.

v) The differences in i), ii), and iii) over time, when possible: these are the differences in in attitudes on transgender managers and employment discrimination using list experiment, direct survey, the size of the social desirability bias over time in comparison with Aksoy et al. (2025) (AEARCTR-0008820: https://doi.org/10.1257/rct.8820).

Secondary Outcomes

Secondary Outcomes (end points)
i) Population beliefs. This is the guessed percent of people in the general [US/UK] population who would agree to each key statement used in the list experiments
ii) Additional survey questions to understand views on gender affirming care
iii) Additional survey questions measuring attitudes and perceptions on LGBTQ+ topics and demographics
iv) Comparisons between UK and US data
Secondary Outcomes (explanation)

Experimental Design

Experimental Design
We use a double list experiment, a variant of the original list experiment pioneered by Miller (1984). In a regular list experiment, participants are either assigned to a control or a treatment group. In the control group, participants are given a list with a set of statements and asked to indicate how many of those statements are true for them. In the treatment group, participants are given the same list with the same set of statements plus one additional sensitive statement (e.g., a statement about attitudes towards LGBTQ+ individuals or policies). The difference in means between the treatment and control group is the estimated share of the population with the key sensitive attribute.

In our case, we exploit the double list experiment technique to increase power, following Glynn (2013). For each sensitive statement, we will have two lists (i.e., Lists 1A and 1B), designed to be positively correlated. Some participants will be randomized into List 1A (control) and List 1B + Key Sensitive Statement (treatment). Other participants will be randomized into List 1A + Key Sensitive Statement (treatment) and List 1B (control). Some participants will get List 1A first, others will get List 1B first (order will be randomized). The differences-in means between control and treatment groups from both lists will be averaged and that will be the share of the population with that key sensitive attribute.
Experimental Design Details
Not available
Randomization Method
First, since each participant will see only one statement from Key Items 1-3 in List Experiment 1, we will randomize participants into one of the possible twelve combinations.

Then, since each participant will see only one statement from Key Items 4-6 in List Experiment 2, we will again randomize participants into one of the possible twelve combinations.

List Experiment 2 will always be shown after List Experiment 1.
Randomization Unit
Individual level randomization
Was the treatment clustered?
No

Experiment Characteristics

Sample size: planned number of clusters
We plan to obtain a representative sample in Prolific using sex, age, and political affiliation as quota selection criteria.
Sample size: planned number of observations
Following the initial pre-registration of our study, we collected pilot data from both the US and the UK. We collected pilot data on 750 participants in the US and 450 participants in the UK. We will include/exclude the pilot datasets from the analysis as a robustness check. Planned number of observations for the main studies: In the US: 900 participants will take the survey without the list experiment. 5850 participants will take the full survey including the list experiment and the direct questions. In the UK: 600 participants will take the survey without the list experiment. 3500 participants will take the full survey including the list experiment and the direct questions. The sample sizes are determined based on the max UK/US representative sample sizes (Factors: sex, age, and political affiliation) as well as budgetary constraints. Conditional on Prolific's sample size constraints and our funding availability, we may need to adjust the sample sizes accordingly.
Sample size (or number of clusters) by treatment arms
For Lists A, we will have 50% of the participants in the treatment group and 50% of the participants in the control group. For Lists B, we will again have 50% of the participants in the treatment and control groups each. However, since we are using a double list experiment technique (which incorporates a within-subject component), participants who are in List A (List B) treatment group will naturally be in List B (List A) control group and vice versa.
Minimum detectable effect size for main outcomes (accounting for sample design and clustering)
IRB

Institutional Review Boards (IRBs)

IRB Name
Rensselaer Institutional Review Board
IRB Approval Date
2025-05-27
IRB Approval Number
2254
IRB Name
Vanderbilt University Human Research Protections Program
IRB Approval Date
2025-08-21
IRB Approval Number
STUDY00000046
IRB Name
FESE UEBS Ethics Committee
IRB Approval Date
2025-09-03
IRB Approval Number
9694200
Analysis Plan

There is information in this trial unavailable to the public. Use the button below to request access.

Request Information